References

1. Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D, Munzel U, Bousquet J. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. Click Here
2. Dymista Summary of Product Characteristics. Link to http://www.medicines.ie/medicine/15709/SPC/Dymista+Nasal+Spray/
3. Meltzer et al. Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis. Int Arch Allergy Immunol 2013;161:369 - 37 Click Here
4. Price P, Bousquet J, Hellings P, et al. Abstract presented at SERIN, Leuven, Belgium, 21-23 March 2013. Click Here
5. Berger W; Shah S; Lieberman P; Hadley J; Price D; Munzel U; Bhatia S. Long-term, randomized, safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis. JACI Clin Pract 2013; in press. Click Here
6. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008. Click Here
7. Pawankar et al. Allergic Rhinitis and Its Impact on Asthma in Asia Pacific and the ARIA Update 2008. Click Here
8. Pawanker, R Allergic Rhinitis and asthma: are they manifestations of one syndrome? 2006; 36: 1-4. Click Here
9. Clatworthy et al. The Value of self-report assessment of adherence, rhinitis and smoking in relation to asthma control. Primary Care Respiratory Journal 2009; 18 (4): 300 - 305. Click Here
10. Bousquet et al. Links between Rhinitis and Asthma. Allergy 2003; 58: 691-706. Click Here